Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.45 (market cap $6.04B), while iShares Broad USD Investment Grade Corporate Bond trades at $49.85 (market cap $17.53B). The key difference: iShares Broad USD Investment Grade Corporate Bond is far larger — about 2.9× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and iShares Broad USD Investment Grade Corporate Bond for 44 Days on average.
| IOVA | USIG | |
|---|---|---|
Market Cap | $6.04B | $17.53B |
Volume | 14,805,993 | 4,695,583 |
Sector | Health | Fixed Income |
52-Week High | $14.82 | $52.69 |
52-Week Low | $1.81 | $48.54 |
Typical Hold Time | 0 Days | 44 Days |
Enterprise Value | $5.97B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
USIG trades at $48.68 with minimal daily movement (+0.06%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The stock faces resistance at $49 with support at $48. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon increasing its stake by 0.9% in Q2 2026.
The outlook remains cautious due to bearish technicals and lack of fundamental data. Investment opportunities include institutional accumulation, but risks involve market volatility and absence of recent financial disclosures. Investors should await updated earnings reports for clearer valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
